| CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers S Vijayaraghavan, C Karakas, I Doostan, X Chen, T Bui, M Yi, ... Nature communications 8 (1), 15916, 2017 | 263 | 2017 |
| Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer JPW Carey, C Karakas, T Bui, X Chen, S Vijayaraghavan, Y Zhao, J Wang, ... Cancer research 78 (3), 742-757, 2018 | 114 | 2018 |
| Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis S Vijayaraghavan, L Lipfert, K Chevalier, BS Bushey, B Henley, R Lenhart, ... Molecular cancer therapeutics 19 (10), 2044-2056, 2020 | 105 | 2020 |
| Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer NM Kettner, S Vijayaraghavan, MG Durak, T Bui, M Kohansal, MJ Ha, ... Clinical Cancer Research 25 (13), 3996-4013, 2019 | 97 | 2019 |
| Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition X Chen, KH Low, A Alexander, Y Jiang, C Karakas, KR Hess, JPW Carey, ... Clinical Cancer Research 24 (24), 6594-6610, 2018 | 94 | 2018 |
| Molecular genetics and cellular events of K-Ras-driven tumorigenesis GG Jinesh, V Sambandam, S Vijayaraghavan, K Balaji, S Mukherjee Oncogene 37 (7), 839-846, 2018 | 94 | 2018 |
| AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers K Balaji, S Vijayaraghavan, L Diao, P Tong, Y Fan, JPW Carey, TN Bui, ... Molecular Cancer Research 15 (1), 45-58, 2017 | 88 | 2017 |
| Inhibiting CDK in cancer therapy: current evidence and future directions S Vijayaraghavan, S Moulder, K Keyomarsi, RM Layman Targeted oncology 13, 21-38, 2018 | 85 | 2018 |
| Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant triple-negative breast cancer NA Jabbour-Leung, X Chen, T Bui, Y Jiang, D Yang, S Vijayaraghavan, ... Molecular cancer therapeutics 15 (4), 593-607, 2016 | 64 | 2016 |
| CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell-cycle arrest AM Francis, A Alexander, Y Liu, S Vijayaraghavan, KH Low, D Yang, ... Molecular cancer therapeutics 16 (9), 1751-1764, 2017 | 51 | 2017 |
| Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action … BC Cho, A Simi, J Sabari, S Vijayaraghavan, S Moores, A Spira Clinical lung cancer 24 (2), 89-97, 2023 | 26 | 2023 |
| CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun 8: 15916 S Vijayaraghavan, C Karakas, I Doostan, X Chen, T Bui, M Yi, ... | 6 | 2017 |
| Characterizing acquired resistance to palbociclib in breast cancer S Vijayaraghavan, I Doostan, JPW Carey, K Keyomarsi Cancer Research 77 (13_Supplement), 2060-2060, 2017 | 4 | 2017 |
| Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies S Moores, S Vijayaraghavan US Patent 11,459,391, 2022 | 2 | 2022 |
| Abstract P5-08-02: Inhibition of CDK4/6 induces senescence and autophagy in ER positive breast cancers S Vijayaraghavan, K Keyomarsi Cancer Research 75 (9_Supplement), P5-08-02-P5-08-02, 2015 | 2 | 2015 |
| Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies S Moores, S Vijayaraghavan US Patent App. 17/817,295, 2023 | 1 | 2023 |
| Fc-mediated mechanism of action for the novel EGFR-cMET bispecific antibody (JNJ-61186372) in non-small cell lung cancer S Vijayaraghavan, B Bushey, L Lipfert, R Nanjunda, ER Lacy, P Buckley, ... Cancer Research 79 (13_Supplement), 4818-4818, 2019 | 1 | 2019 |
| An intact G1/S checkpoint determines response to CDK4/6 inhibitor in breast cancer S Vijayaraghavan, K Keyomarsi Cancer Research 76 (14_Supplement), 2989-2989, 2016 | 1 | 2016 |
| Pharmacological inhibition of CDK4/6 induces G1 arrest, autophagy and senescence in ER+ breast cancer S Vijayaraghavan, K Keyomarsi Cancer Research 75 (15_Supplement), 1783-1783, 2015 | 1 | 2015 |
| Abstract LB122: JNJ-87890387, a novel ENPP3 bispecific T-cell redirector (ENPP3xCD3) with tumor selectivity through targeting apical surface antigens S Vijayaraghavan, P Seth, A Winkis, K Chevalier, A Marthaler, ... Cancer Research 84 (7_Supplement), LB122-LB122, 2024 | | 2024 |
